

the ACA and hence eligible for the Rate Review Grants. 46 States and 5 U.S. territories plus the District of Columbia were awarded grants. CCHIO is seeking to publish the Cycle II Funding Opportunity Announcement and associated grantee reporting requirements consisting of (4) Quarterly reports, rate review transaction data (quarterly), (1) annual report per year, and (1) final report from all grantees. This information collection is required for effective monitoring of grantees and to fulfill statutory requirements under Section 2794(b)(1)(a) that requires grantees, as a condition of receiving a grant authorized under Section 2794(c), to report to The Secretary information about premium increases. *Form Number:* CMS-10380 (OCN: 0938-1121); *Frequency:* Annually, On Occasion; *Affected Public:* Public Sector; State and Territory Governments; *Number of Respondents:* 107; *Number of Responses:* 1,075; *Total Annual Hours* 42,872. (For policy questions regarding this collection, contact Jacqueline Roche at 301-492-4171. For all other issues call (410) 786-1326.)

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS' Web site at <http://www.cms.gov/PaperworkReductionActof1995/PRAL/list.asp#TopOfPage> or e-mail your request, including your address, phone number, OMB number, and CMS document identifier, to [Paperwork@cms.hhs.gov](mailto:Paperwork@cms.hhs.gov), or call the Reports Clearance Office at 410-786-1326.

In commenting on the proposed information collections please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must be submitted in one of the following ways by *July 15, 2011*:

1. Electronically. You may submit your comments electronically to <http://www.regulations.gov>. Follow the instructions for "Comment or Submission" or "More Search Options" to find the information collection document(s) accepting comments.

2. By regular mail. *You may mail written comments to the following address:* CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attention: Document Identifier/OMB Control Number, Room C4-26-05, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

Dated: May 10, 2011.

**Martique Jones,**

*Director, Regulations Development Group, Division B, Office of Strategic Operations and Regulatory Affairs.*

[FR Doc. 2011-11836 Filed 5-13-11; 8:45 am]

**BILLING CODE 4120-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket Nos. FDA-2009-E-0084 and FDA-2009-E-0086]**

#### Determination of Regulatory Review Period for Purposes of Patent Extension; PRISTIQ; Correction and Reopening of the Comment Period

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction and reopening of the comment period.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting notices concerning FDA's determination of the regulatory review period for PRISTIQ that appeared in the **Federal Registers** of August 31, 2010 (75 FR 53314) and September 2, 2010 (75 FR 53969). The documents omitted docket number FDA-2009-E-0086. This document corrects those omissions. Because the comment period for the notices closed on February 28, 2011, FDA is reopening the comment period to allow interested parties to submit comments or petitions to docket number FDA-2009-E-0086.

**DATES:** Submit either electronic or written comments and written petitions by June 15, 2011.

**ADDRESSES:** Submit electronic comments to <http://www.regulations.gov>. Submit written petitions along with three copies and written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** Beverly Friedman, Office of Regulatory Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6222, Silver Spring, MD 20993-0002, 301-796-3602.

#### SUPPLEMENTARY INFORMATION:

##### I. Correction

In FR Doc. 2010-21586, appearing on page 53314, in the **Federal Register** of Tuesday, August 31, 2010, the following correction is made:

1. On page 53314, in the first column, in the heading of the document,

"[Docket No. FDA-2009-E-0084]" is corrected to read "[Docket Nos. FDA-2009-E-0084 and FDA-2009-E-0086]".

In FR Doc. C1-2010-21586, appearing on page 53969, in the **Federal Register** of Thursday, September 2, 2010, the following correction is made:

2. On page 53969, in the third column, in the heading of the document, "[Docket No. FDA-2009-E-0084]" is corrected to read "[Docket Nos. FDA-2009-E-0084 and FDA-2009-E-0086]".

##### II. Comments and Petitions

FDA's notice concerning the Agency's determination of the regulatory review period for PRISTIQ (75 FR 53314) inadvertently omitted docket number FDA-2009-E-0086. Because the period for submitting comments and petitions closed on February 28, 2011, FDA is reopening the comment period to provide the opportunity for interested parties to submit comments or petitions to docket number FDA-2009-E-0086.

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) electronic or written comments and written petitions. It is no longer necessary to send three copies of mailed comments. However, if you submit a written petition, you must submit three copies of the petition. Identify comments with docket number FDA-2009-E-0086. Comments and petitions that have not been made publicly available on [regulations.gov](http://regulations.gov) may be viewed in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Dated: April 28, 2011.

**Jane A. Axelrad,**

*Associate Director for Policy, Center for Drug Evaluation and Research.*

[FR Doc. 2011-11903 Filed 5-13-11; 8:45 am]

**BILLING CODE 4160-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Neurodifferentiation, Plasticity, and Regeneration Study Section, June 1, 2011, 8 a.m. to June 2, 2011, 4 p.m., Westin Alexandria, 400 Courthouse Square, Alexandria, VA 22314 which was published in the **Federal Register** on May 9, 2011, 76 FR 26736-26737.

The meeting will be held at the Hotel Monaco, 480 King Street, Alexandria, VA 22314. The meeting dates and time